Childhood B-acute Lymphoblastic Leukaemia and Role of CD9 Gene Regulation in Relapse
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age0-17
SponsorRennes University Hospital
About this trial
B-acute lymphoblastic leukaemia (B-ALL) is the most common cancer in children, with 20% of patients relapsing. CD9, a transmembrane protein, is linked to the migratory and adhesion capacities of leukaemia cells and could be associated with relapses. The aim of this project is to understand how CD9 regulation can be a marker of potential relapses, using bone and blood sampling of newly diagnosed patients at 3 crucial moments of therapy.
Eligibility criteria
Qualifiers
Under 18 years
With established diagnosis of B-ALL
Initial diagnosis made in the investigating centre
Having received oral and written information about the protocol, or oral only if the patient is unable to read.
Disqualifiers
Isolated extramedullary involvement at inclusion
Patient of childbearing age without effective contraception.
Adult subject to legal protection (safeguard of justice, curatorship, guardianship), person deprived of liberty.
Trial design
Treatments tested in this trial
- Sampling bone tissue and blood
Treatment groups
50 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov